EXAC News and Headlines - Exactech Inc
The guru exited his Snyder's-Lance Inc. (LNCE) stake, impacting the portfolio by -0.73%.
The company, which manufactures and distributes a variety of packaged snack foods, has a market cap of $4.92 billion and an enterprise value of $5.99 billion.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. While its return on equity of 7.90% is underperforming the sector, its return on assets of 4.01% is outperforming 52% of companies in
Exact Sciences Corp. (EXAC) declined after an independent panel of health care experts excluded the company’s colon cancer-screening test from a list of recommended tests in the U.S. Instead, the panel defined the product as “alternative testing that may be useful in select clinical circumstances.” Marketed as Cologuard, the product is a non-invasive, FDA-approved colorectal cancer-screening test covered by Medicare. It has proven effective at detecting early-stage colon cancer as well as precancerous lesions. When detected early, colon cancer is highly curable. However, Cologuard’s exclusion from the panel’s list of recommended tests may make it more difficult to win favorable
|2013-06-28 $ 19.75 (3.62%)|
Mario Gabelli Ups His Holdings in EXAC, TWIN and LAYN - GuruFocus.com
|2011-03-16 $ 17.84 (-0.34%)|
Exactech Inc. Reports Operating Results (10-K) - GuruFocus.com
|2010-11-09 $ 17.79 (3.25%)|
|2010-05-05 $ 19.4 (0.57%)|
|2010-05-04 $ 19.29 (-4.17%)|
|2009-12-12 $ 16.84 (1.69%)|
|2009-11-05 $ 16.72 (5.62%)|
|2009-08-07 $ 14 (-0.57%)|
|2009-05-08 $ 13.67 (1.11%)|